Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer

• Phase: Phase 2

Details

• Lead Sponsor: University of Wisconsin, Madison
• Collaborator: Aventis Pharmaceuticals
• Treatments: Carboplatin; Docetaxel

Criteria

Inclusion Criteria:

• Recurrent ovarian or peritoneal cancer

Exclusion Criteria:

• No prior chemotherapy